This post was originally published on this site With a $544,360 developmental grant from the U.S. Department of Defense (DoD), four research teams are joining efforts to identify biomarkers of ovarian cancer with a goal of detecting the disease earlier or before it even develops. The collaboration, named DoD and SPORE Ovarian Cancer Omics Consortium,…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Venclexta-Darzalex Combos Show Strong Response Rates in Multiple Myeloma Trial, Early Data Show
This post was originally published on this site Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who failed prior treatment, particularly those with a common genetic abnormality called t(11;14), new Phase 1/2 data show. The combination reduced tumor burden in nearly all — 92%…
Orencia Given FDA’s Breakthrough Status as Treatment to Prevent Graft-versus-Host Disease After Stem Cell Transplant
This post was originally published on this site Bristol-Myers Squibb‘s arthritis medicine Orencia (abatacept) has been named Breakthrough Therapy by the U.S. Food and Drug Administration for the prevention of acute graft-versus-host disease (GvHD) in patients who received a stem cell transplant from an unrelated donor, the company has announced. The designation intends to accelerate…
Subgroup of Active T-cells Linked to Worse Disease in Sarcoidosis, Study Reports
This post was originally published on this site The lungs of patients with sarcoidosis are burdened with a more active subset of immune T-cells, called mucosal-associated invariant T (MAIT) cells, a study reports. The activity of these MAIT cells correlates with worse disease, supporting their potential as therapeutic targets, the researchers said. The study, “Activation…
Lighter Days Are Around the Corner
This post was originally published on this site “Oh, by the way,” she said nonchalantly as I entered the room. “Your scans are clear.” “I’m sorry, what?” I stuttered in disbelief. Just like that, in a matter of seconds, my oncologist revealed the news I had waited, hoped, and prayed over a year for. Four…
FDA Grants N-803 Combo Breakthrough Therapy Status for Non-Muscle Invasive Bladder Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ImmunityBio‘s interleukin-15 (IL-15) agonist N-803, in combination with Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle invasive bladder carcinoma in situ (CIS) that does not respond to BCG treatment alone. The designation is intended…
HHS Grant to Advance Breast Cancer Screenings Based on Ultrasound
This post was originally published on this site A U.S. Department of Health and Human Services grant will fund research at two universities into whether an ultrasound technology might be more effective than mammography at detecting breast cancer, particularly in younger people. At present, mammography is most often used to screen for and diagnose breast cancers.…
Onvansertib Helps Overcome Resistance to Zytiga in mCRPC Patients, Interim Phase 2 Data Show
This post was originally published on this site Trovagene’s investigational oral therapy onvansertib may help overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), updated Phase 2 data continue to suggest. The trial (NCT03414034) is testing onvansertib as an add-on to Zytiga (by Janssen Biotech) and prednisone in men who experienced…
China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations
This post was originally published on this site Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. Lynparza is now the first PARP enzyme inhibitor approved in that…
Kyprolis Combo Followed by Stem Cell Transplant is Effective for Most Smoldering Multiple Myeloma, Data Show
This post was originally published on this site A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after a stem cell transplant, is effective for the treatment of patients with smoldering multiple myeloma — a precursor condition to multiple myeloma — at high risk of progressing to the full blown disease,…
HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases
This post was originally published on this site Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious…
Tecentriq-chemo Combo OK’d as First-line Treatment for Certain Metastatic NSCLC Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with chemotherapy — Abraxane (nab-paclitaxel) plus carboplatin — as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors do not have any mutations in the EGFR or ALK genes. Tecentriq is…